The UW School of Pharmacy is now housing a new center researching the effects of psychedelic drugs like psilocybin and MDMA as a possible treatment for conditions like depression, post traumatic stress disorder, and opioid addiction. The UW Madison Transdisciplinary Center for Research in Psychoactive Substances is looking into the long stigmatized drugs that are now rising in profile as mental illness treatment options.
Paul Hutson is the Director of the Center at UW and has been a pharmacist with the UW Madison School of Pharmacy for 33 years. He has worked at UW Madison in the areas of experimental cancer therapeutics and palliative care, and 7 years ago was given the opportunity to lead a pivotal dosing and safety trial of psilocybin. He is also a co-investigator on the more recent clinical trials of psilocybin and MDMA being performed at the UW Madison. He joins Friday Buzz hosts Ankur Malhotra and Austin Exum to talk more about the new center.
(Images courtesy of Christopher Ott on Unsplash and Paul Hutson)
